News

Results of Phase III ReMoxTB Clinical Trial Published

Moxifloxacin

Results of the Phase III REMoxTB clinical trial were published in the New England Journal of Medicine on September 7th, 2014. REMox or Rapid Evaluation of Moxifloxacin in Tuberculosis (REMoxTB) was a trial designed to determine whether replacement of either ethambutol or isoniazid with moxifloxacin shortened the duration of therapy. In summary, while the regimens with moxifloxacin caused a more rapid decrease in mycobacterial load, moxifloxacin containing regimens did not shorten TB treatment to 4 months as predicted.

For more information on the REMoxTB trial results, see here for the TB Alliance press release.

Related Links

Publication in New England Journal of Medicine

TB Alliance Press Release

TB Alliance Graphic

PanACEA: A new approach to tuberculosis research

Moxifloxacin struggles against current TB Drugs: REMox Trials

Additional Links

REMox TB Consortium

TB Alliance

More News
22 Jul 2024
The National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) has issued a $30.8 million grant to the Preclinical Design and Clinical Translation of TB Regimens (PreDiCTR) consortium , a new consortium co-led by investigators from Weill Cornell Medicine; the...
27 Jun 2024
On May 17, the World Health Organization (WHO) released its updated  Bacterial Priority Pathogens List (BPPL) 2024 and for the first time in its history it included a drug resistant strain of Mycobacterium tuberculosis. Along with three other new families of antibiotic-resistant bacterial pathogens...
19 Mar 2024
For World TB Day 2024, the WGND is spotlighting a monumental achievement in TB drug research and development: the Global TB Drug Pipeline has never been bigger than it is today. The number of drug candidates being clinically evaluated for use in the treatment of adult pulmonary TB has surpassed...